Windtree Therapeutics (OTCMKTS: WINT) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Insider & Institutional Ownership
0.0% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Puma Biotechnology shares are held by institutional investors. 0.8% of Windtree Therapeutics shares are held by company insiders. Comparatively, 21.1% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Windtree Therapeutics and Puma Biotechnology’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Windtree Therapeutics||$2.04 million||5.11||-$39.49 million||($71.80)||-0.05|
|Puma Biotechnology||$26.20 million||104.31||-$291.95 million||($7.85)||-9.23|
Windtree Therapeutics has higher earnings, but lower revenue than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Windtree Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.
This table compares Windtree Therapeutics and Puma Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Windtree Therapeutics and Puma Biotechnology, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Puma Biotechnology has a consensus target price of $103.11, suggesting a potential upside of 42.32%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Puma Biotechnology is more favorable than Windtree Therapeutics.
Puma Biotechnology beats Windtree Therapeutics on 10 of the 14 factors compared between the two stocks.
About Windtree Therapeutics
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.